Title |
A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
|
---|---|
Published in |
PLOS ONE, May 2013
|
DOI | 10.1371/journal.pone.0063818 |
Pubmed ID | |
Authors |
David Gardiner, Jay Lalezari, Eric Lawitz, Michael DiMicco, Rheem Ghalib, K. Rajender Reddy, Kyong-Mi Chang, Mark Sulkowski, Steven O’ Marro, Jeffrey Anderson, Bing He, Vikram Kansra, Fiona McPhee, Megan Wind-Rotolo, Dennis Grasela, Mark Selby, Alan J. Korman, Israel Lowy |
Abstract |
Expression of the programmed death 1 (PD-1) receptor and its ligands are implicated in the T cell exhaustion phenotype which contributes to the persistence of several chronic viral infections, including human hepatitis C virus (HCV). The antiviral potential of BMS-936558 (MDX-1106) - a fully human anti-PD-1 monoclonal immunoglobulin-G4 that blocks ligand binding - was explored in a proof-of-concept, placebo-controlled single-ascending-dose study in patients (N = 54) with chronic HCV infection. Interferon-alfa treatment-experienced patients (n = 42) were randomized 5∶1 to receive a single infusion of BMS-936558 (0.03, 0.1, 0.3, 1.0, 3.0 mg/kg [n = 5 each] or 10 mg/kg [n = 10]) or of placebo (n = 7). An additional 12 HCV treatment-naïve patients were randomized to receive 10 mg/kg BMS-936558 (n = 10) or placebo (n = 2). Patients were followed for 85 days post-dose. Five patients who received BMS-936558 (0.1 [n = 1] or 10 mg/kg) and one placebo patient achieved the primary study endpoint of a reduction in HCV RNA ≥0.5 log10 IU/mL on at least 2 consecutive visits; 3 (10 mg/kg) achieved a >4 log10 reduction. Two patients (10 mg/kg) achieved HCV RNA below the lower limit of quantitation (25 IU/mL), one of whom (a prior null-responder) remained RNA-undetectable 1 year post-study. Transient reductions in CD4(+), CD8(+) and CD19(+) cells, including both naïve and memory CD4(+) and CD8(+) subsets, were observed at Day 2 without evidence of immune deficit. No clinically relevant changes in immunoglobulin subsets or treatment-related trends in circulating cytokines were noted. BMS-936558 exhibited dose-related exposure increases, with a half-life of 20-24 days. BMS-936558 was mostly well tolerated. One patient (10 mg/kg) experienced an asymptomatic grade 4 ALT elevation coincident with the onset of a 4-log viral load reduction. Six patients exhibited immune-related adverse events of mild-to-moderate intensity, including two cases of hyperthyroidism consistent with autoimmune thyroiditis. Further investigation of PD-1 pathway blockade in chronic viral disease is warranted. ClinicalTrials.gov NCT00703469. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 20% |
Unknown | 4 | 80% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 1% |
United Kingdom | 1 | <1% |
Colombia | 1 | <1% |
Unknown | 164 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 41 | 24% |
Student > Ph. D. Student | 30 | 18% |
Student > Bachelor | 18 | 11% |
Student > Master | 14 | 8% |
Student > Doctoral Student | 12 | 7% |
Other | 28 | 17% |
Unknown | 25 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 48 | 29% |
Agricultural and Biological Sciences | 27 | 16% |
Immunology and Microbiology | 24 | 14% |
Biochemistry, Genetics and Molecular Biology | 9 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
Other | 17 | 10% |
Unknown | 36 | 21% |